多學科診療模式下不可切除肝細胞癌“雙轉化”后R0切除：附1例報道_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Supervisor：Ministry of Education of the People’s Republic of China Sponsor：West China Hospital, Sichuan University
Editor-in-chief：Wu Hong
Publishing period： Monthly ISSN：1007-9424 CN：51-1505/R

多學科診療模式下不可切除肝細胞癌“雙轉化”后R0切除：附1例報道

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY | 2026, 33(6): 825-827
First online：

Article Views：2388
PDF Downloads：10
Cited by：0

Authors：

龐北川 , 麥剛 , 李友偉 ,  陳健 ,  李鋒

德陽市人民醫院肝膽胰外科·德陽市人民醫院消化疾病中心（四川德陽 618000）;

Corresponding?author：

陳健, Email: chenhealth@163.com; 李鋒, Email: 1340482261@qq.com

Keywords：

肝細胞癌; 轉化治療; 多學科診療; 門靜脈栓塞; R0切除

DOI：

10.7507/1007-9424.202602049

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 龐北川, 麥剛, 李友偉, 陳健, 李鋒. 多學科診療模式下不可切除肝細胞癌“雙轉化”后R0切除：附1例報道. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2026, 33(6): 825-827. doi: 10.7507/1007-9424.202602049 Copy

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.	Yang X, Sun H, Hu B, et al. Adjuvant camrelizumab combined with apatinib treatment after resection of hepatocellular carcinoma in CNLC Ⅱ and Ⅲ stage: a single-center prospective phase Ⅱ trial. Ann Oncol, 2021, 32(Suppl 5): S824. doi: 10.1016/j.annonc.2021.08.164.
16.
17.

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15. Yang X, Sun H, Hu B, et al. Adjuvant camrelizumab combined with apatinib treatment after resection of hepatocellular carcinoma in CNLC Ⅱ and Ⅲ stage: a single-center prospective phase Ⅱ trial. Ann Oncol, 2021, 32(Suppl 5): S824. doi: 10.1016/j.annonc.2021.08.164.
16.
17.

Previous Article
定向斑塊切除聯合藥物涂層球囊在股腘動脈長段閉塞性病變中的應用
Next Article
直腸神經內分泌腫瘤伴巨大肝轉移灶：附1例報道

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

多學科診療模式下不可切除肝細胞癌“雙轉化”后R0切除：附1例報道

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content